6 November 2015
BSI, the business standards company, today announced the appointment of Douglas Hurt as a Non-Executive Director with effect from 1 November 2015.
Until February 2015 Douglas was the Group Finance Director of the international engineering group, IMI plc, which he joined in 2006 from GlaxoSmithKline. He began his career in PricewaterhouseCoopers where he qualified as an accountant before joining Glaxo Holdings plc. During his long career in the GSK group he held many senior roles, including Managing Director, Glaxo Wellcome UK. He has worked in the UK and internationally and his career spans finance, general management, R&D and strategy.
He is currently a Non-Executive Director of Tate & Lyle PLC and Vesuvius plc. At BSI he will be a member of the Audit, Remuneration and Nominations Committees.
Sir David Brown, Chairman of BSI said: “I am delighted to welcome Douglas Hurt to the Board of BSI. The company will benefit greatly from the knowledge and insights he has accumulated during his impressive career. His wealth of commercial experience will be of considerable value to BSI Group.”
Speaking about his new role with BSI, Douglas Hurt said: “BSI is a uniquely important company that plays a vital role in helping to build excellence in businesses around the world in a wide range of key business sectors. I am delighted to be joining its Board.”